Home Clinical Topics FDA approves antiplatelet drug for use during PCI

FDA approves antiplatelet drug for use during PCI

On June 22, the U.S. Food and Drug Administration (FDA) approved Kengreal (cangrelor), an I.V. antiplatelet drug, for use in adults undergoing undergoing percutaneous coronary intervention (PCI). Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here